Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
On Tuesday, Enveric Biosciences’ (NASDAQ:ENVB) wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on treating joint disease.
The companies have executed two licenses for Akos’ cannabinoid-COX-2 conjugate compounds for pharmaceutical and potential non-pharmaceutical applications.
The two licenses grant Restoration Biologics use of the technology for all human and animal applications. Restoration Biologics initially plans to focus on joint pathology, such as osteoarthritis and rheumatoid arthritis.
The two exclusive, royalty-bearing global licenses provide Restoration Biologics with full control over developing, marketing, and commercializing the conjugate compounds, which …